Women’s Health Dx
Sera Prognostics Partners With Anthem and HealthCore to Improve Outcomes for Preterm Babies
January 05, 2021- Patient enrollment began in November for this rigorous prospective, randomized, controlled PRIME intervention trial to demonstrate the value of implementing the PreTRM® prevention strategy to improve neonatal outcomes and lower cost of care. Read More >
Sera Prognostics to Present at Baird’s 2020 Global Health Care Conference
September 9, 2020- Sera will be presenting at the upcoming Baird 2020 Global Health Care Conference. A virtual conference, Sera’s presentation will take place on Thursday, September 10 at 10:50 a.m. ET. Read More >
Sera Prognostics Appoints Thomas J. Garite, M.D. as Vice President of Clinical Sciences
June 24, 2020 - Sera announced the appointment Thomas J. Garite, M.D. as Vice President of Clinical Sciences. - Dr. Garite will support clinical development and operations as Sera transitions from clinical to commercial-stage company. Read More >
WHO WE ARE
PROVIDING INDIVIDUALIZED RISK ASSESSMENT TO PREDICT AND MANAGE PREMATURE BIRTH, PREECLAMPSIA, AND OTHER PREGNANCY COMPLICATIONS
Sera Prognostics is dedicated to improve the lives of women and babies through individualized prenatal care. Sera’s strategy is to deliver pivotal information to physicians to improve health and to improve the economics of healthcare delivery for pregnant women. Our first test, the PreTRM® Test, focuses on the early prediction of preterm birth risk, one of the most serious pregnancy complications which affects almost one in ten pregnancies in the U.S. alone.
Early and accurate prediction of risk for pregnancy complications helps pregnant women and their doctors better understand risks and proactively address risks of adverse pregnancy outcomes. Learn about the PreTRM® Test for Risk Management.